Terms: = Prostate cancer AND STK11, LKB1, 6794, ENSG00000118046, Q15831, PJS
43 results:
1. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract] [Full Text] [Related]
2. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
3. Auraptene Enhances AMP-Activated Protein Kinase Phosphorylation and Thereby Inhibits the Proliferation, Migration and Expression of Androgen Receptors and prostate-Specific Antigens in prostate cancer Cells.
Akasaka Y; Hasei S; Ohata Y; Kanna M; Nakatsu Y; Sakoda H; Fujishiro M; Kushiyama A; Ono H; Matsubara A; Hinata N; Asano T; Yamamotoya T
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958994
[No Abstract] [Full Text] [Related]
4. STAT3/lkb1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract] [Full Text] [Related]
5. Mutations in epigenetic regulator
Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
[TBL] [Abstract] [Full Text] [Related]
6. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
7. Capilliposide B inhibits the migration of prostate cancer by inducing autophagy through the ROS/AMPK/mTOR pathway.
Wang L; Han H; Feng Y; Ma J; Han Z; Li R; Zhu W; Li S; Tian J; Zhang L
Phytother Res; 2023 Jul; 37(7):2902-2914. PubMed ID: 36867511
[TBL] [Abstract] [Full Text] [Related]
8. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
9. Sequential monoscopic image-guided motion compensation in tomotherapy stereotactic body radiotherapy (SBRT) for prostate cancer.
Lu L; Chao E; Zhu T; Wang AZ; Lian J
Med Phys; 2023 Jan; 50(1):518-528. PubMed ID: 36397645
[TBL] [Abstract] [Full Text] [Related]
10. Identification of a Molecularly-Defined Subset of Breast and Ovarian cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
[TBL] [Abstract] [Full Text] [Related]
11. No Tumor Suppressor Role for
Koseoglu H; Celebi A; Galamiyeva G; Dalay N; Ozkardes H; Buyru N
DNA Cell Biol; 2021 Sep; 40(9):1222-1229. PubMed ID: 34370601
[TBL] [Abstract] [Full Text] [Related]
12. PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating lkb1.
Mung KL; Eccleshall WB; Santio NM; Rivero-Müller A; Koskinen PJ
Cell Commun Signal; 2021 Jun; 19(1):68. PubMed ID: 34193159
[TBL] [Abstract] [Full Text] [Related]
13. Current Status and Application of Metformin for prostate cancer: A Comprehensive Review.
Ahn HK; Lee YH; Koo KC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198356
[TBL] [Abstract] [Full Text] [Related]
14. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
15. Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer.
Aronson M; Swallow C; Govindarajan A; Semotiuk K; Cohen Z; Kaurah P; Velsher L; Ambus I; Buckley K; Forster-Gibson C; Meschino WS; Blumenthal A; Kim RH; Brar S
Curr Oncol; 2020 Apr; 27(2):e182-e190. PubMed ID: 32489267
[TBL] [Abstract] [Full Text] [Related]
16. Genetic manipulation of lkb1 elicits lethal metastatic prostate cancer.
Hermanova I; Zúñiga-García P; Caro-Maldonado A; Fernandez-Ruiz S; Salvador F; Martín-Martín N; Zabala-Letona A; Nuñez-Olle M; Torrano V; Camacho L; Lizcano JM; Talamillo A; Carreira S; Gurel B; Cortazar AR; Guiu M; López JI; Martinez-Romero A; Astobiza I; Valcarcel-Jimenez L; Lorente M; Arruabarrena-Aristorena A; Velasco G; Gomez-Muñoz A; Suárez-Cabrera C; Lodewijk I; Flores JM; Sutherland JD; Barrio R; de Bono JS; Paramio JM; Trka J; Graupera M; Gomis RR; Carracedo A
J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32219437
[TBL] [Abstract] [Full Text] [Related]
17. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract] [Full Text] [Related]
18. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract] [Full Text] [Related]
19. Concurrent regulation of lkb1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties.
MacDonald AF; Bettaieb A; Donohoe DR; Alani DS; Han A; Zhao Y; Whelan J
BMC Complement Altern Med; 2018 Jun; 18(1):188. PubMed ID: 29914450
[TBL] [Abstract] [Full Text] [Related]
20. CO suppresses prostate cancer cell growth by directly targeting lkb1/AMPK/mTOR pathway in vitro and in vivo.
Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
[TBL] [Abstract] [Full Text] [Related]
[Next]
